For critically ill patients stuck in coma or minimally conscious states, a new systematic review suggests neurostimulants — drugs that boost brain activity — may offer a meaningful path toward recovery. Researchers from Stanford University and the University of Florida analyzed 35 studies, including 11 randomized controlled trials, and found that agents like amantadine, methylphenidate, and modafinil were associated with short-term improvements in arousal and clinical outcomes in ICU patients with disorders of consciousness (DoC).

Amantadine showed the most consistent benefit across nonrandomized studies, with all 8 studies reporting improved Glasgow Coma Scale (GCS) scores and all 3 mortality-reporting studies showing a relative reduction in death. Methylphenidate reduced ICU length of stay and improved GCS in two trials, while modafinil showed modest gains in daytime wakefulness.

Key Takeaways:

• Amantadine outperformed citicoline in head-to-head comparison; methylphenidate outperformed apomorphine
• Evidence is largely driven by traumatic brain injury populations — data in non-brain-injury ICU patients is scarce
• Outcome measures varied widely, limiting cross-study comparisons

Why it matters: Disorders of consciousness are among the most clinically challenging conditions in the ICU, with few established treatment options. These findings highlight neurostimulants as a promising — though not yet definitive — therapeutic avenue, underscoring the urgent need for larger, standardized trials.